Works matching IS 17407745 AND DT 2024 AND VI 21
Results: 87
Abstracts from the Society for Clinical Trials 45th Annual Meeting (2024).
- Published in:
- 2024
- Publication type:
- Abstract
Participant's treatment guesses and adverse events in back pain trials: Nocebo in action?
- Published in:
- 2024
- By:
- Publication type:
- Letter
Commentary on Astrachan et al. The transmutation of research risk in pragmatic clinical trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 666, doi. 10.1177/17407745241266168
- By:
- Publication type:
- Article
Individualized clinical decisions within standard-of-care pragmatic clinical trials: Implications for consent.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 659, doi. 10.1177/17407745241266155
- By:
- Publication type:
- Article
Taking clinical decisions seriously in standard-of-care pragmatic clinical trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 669, doi. 10.1177/17407745241266152
- By:
- Publication type:
- Article
A comparison of alternative ranking methods in two-stage clinical trials with multiple interventions: An application to the anxiolysis for laceration repair in children trial.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 734, doi. 10.1177/17407745241251812
- By:
- Publication type:
- Article
Efficient designs for three-sequence stepped wedge trials with continuous recruitment.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 723, doi. 10.1177/17407745241251780
- By:
- Publication type:
- Article
A comparison of computational algorithms for the Bayesian analysis of clinical trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 689, doi. 10.1177/17407745241247334
- By:
- Publication type:
- Article
Comparison of Bayesian and frequentist monitoring boundaries motivated by the Multiplatform Randomized Clinical Trial.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 701, doi. 10.1177/17407745241244801
- By:
- Publication type:
- Article
Reconsidering stepped wedge cluster randomized trial designs with implementation periods: Fewer sequences or the parallel-group design with baseline and implementation periods are potentially more efficient.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 710, doi. 10.1177/17407745241244790
- By:
- Publication type:
- Article
Considerations for open-label randomized clinical trials: Design, conduct, and analysis.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 681, doi. 10.1177/17407745241244788
- By:
- Publication type:
- Article
Design and implementation of community consultation for research conducted under exception from informed consent regulations for the PreVent and the PreVent 2 trials: Changes over time and during the COVID-19 pandemic.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 671, doi. 10.1177/17407745241243045
- By:
- Publication type:
- Article
Accrual Quality Improvement Program for clinical trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 744, doi. 10.1177/17407745241243027
- By:
- Publication type:
- Article
Challenges in conducting efficacy trials for new COVID-19 vaccines in developed countries.
- Published in:
- Clinical Trials, 2024, v. 21, n. 6, p. 754, doi. 10.1177/17407745241238925
- By:
- Publication type:
- Article
Society for Clinical Trials Data Monitoring Committee initiative website: Closing the gap.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Proceedings of the University of Pennsylvania 15th annual conference on statistical issues in clinical trials: Advances in time-to-event analyses in clinical trials—challenges and opportunities.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 529, doi. 10.1177/17407745241276119
- By:
- Publication type:
- Article
15th Annual University of Pennsylvania conference on statistical issues in clinical trial/advances in time to event analyses in clinical trials (morning panel discussion).
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 562, doi. 10.1177/17407745241272012
- By:
- Publication type:
- Article
15th Annual University of Pennsylvania conference on statistical issues in clinical trial/advances in time-to-event analyses in clinical trials (afternoon panel discussion).
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 612, doi. 10.1177/17407745241271939
- By:
- Publication type:
- Article
Estimands in clinical trials of complex disease processes.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 604, doi. 10.1177/17407745241268054
- By:
- Publication type:
- Article
Analysis of composite time-to-event endpoints in cardiovascular outcome trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 576, doi. 10.1177/17407745241267999
- By:
- Publication type:
- Article
Using multistate models with clinical trial data for a deeper understanding of complex disease processes.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 531, doi. 10.1177/17407745241267862
- By:
- Publication type:
- Article
Statistical approaches for component-wise censored composite endpoints.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 595, doi. 10.1177/17407745241265628
- By:
- Publication type:
- Article
Inferences for the distribution of the duration of response in a comparative clinical study.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 541, doi. 10.1177/17407745241264188
- By:
- Publication type:
- Article
Defining estimand for the win ratio: Separate the true effect from censoring.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 584, doi. 10.1177/17407745241259356
- By:
- Publication type:
- Article
Multiply robust estimation of principal causal effects with noncompliance and survival outcomes.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 553, doi. 10.1177/17407745241251773
- By:
- Publication type:
- Article
Critical importance of correctly defining and reporting secondary endpoints when assessing the ethics of research biopsies.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 650, doi. 10.1177/17407745241244753
- By:
- Publication type:
- Article
Reply to Heitjan's commentary.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 638, doi. 10.1177/17407745241243311
- By:
- Publication type:
- Article
Causal interpretation of the hazard ratio in randomized clinical trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 623, doi. 10.1177/17407745241243308
- By:
- Publication type:
- Article
Comment on "Causal interpretation of the hazard ratio in randomized clinical trials" by Fay and Li.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 636, doi. 10.1177/17407745241243307
- By:
- Publication type:
- Article
The overlap between randomised evaluations of recruitment and retention interventions: An updated review of recruitment (Online Resource for Recruitment in Clinical triAls) and retention (Online Resource for Retention in Clinical triAls) literature.
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 640, doi. 10.1177/17407745241238444
- By:
- Publication type:
- Article
Is inadequate risk stratification diluting hazard ratio estimates in randomized clinical trials?
- Published in:
- Clinical Trials, 2024, v. 21, n. 5, p. 571, doi. 10.1177/17407745231222448
- By:
- Publication type:
- Article
Response to Harrell's commentary.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 415, doi. 10.1177/17407745241251851
- By:
- Publication type:
- Article
Commentary on van Lancker et al.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 412, doi. 10.1177/17407745241251609
- By:
- Publication type:
- Article
Covariate adjustment in randomized controlled trials: General concepts and practical considerations.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 399, doi. 10.1177/17407745241251568
- By:
- Publication type:
- Article
Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 500, doi. 10.1177/17407745241238443
- By:
- Publication type:
- Article
Rethinking the clinical research protocol: Lessons learned from the COVID-19 pandemic and recommendations for reducing noncompliance.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 491, doi. 10.1177/17407745241232430
- By:
- Publication type:
- Article
A safety estimand for late phase clinical trials where the analysis period varies over the subjects.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 483, doi. 10.1177/17407745241230933
- By:
- Publication type:
- Article
Assessing the current utilization status of wearable devices in clinical research.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 470, doi. 10.1177/17407745241230287
- By:
- Publication type:
- Article
The use of linked administrative data in Australian randomised controlled trials: A scoping review.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 516, doi. 10.1177/17407745231225618
- By:
- Publication type:
- Article
Research encouraging off-label use of quetiapine: A systematic meta-epidemiological analysis.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 418, doi. 10.1177/17407745231225470
- By:
- Publication type:
- Article
Public involvement in Australian clinical trials: A systematic review.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 507, doi. 10.1177/17407745231224533
- By:
- Publication type:
- Article
Assessing the impact of risk-based data monitoring on outcomes for a paediatric multicentre randomised controlled trial.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 461, doi. 10.1177/17407745231222019
- By:
- Publication type:
- Article
Hierarchical Bayesian modeling of heterogeneous outcome variance in cluster randomized trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 451, doi. 10.1177/17407745231222018
- By:
- Publication type:
- Article
A Bayesian adaptive design approach for stepped-wedge cluster randomized trials.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 440, doi. 10.1177/17407745231221438
- By:
- Publication type:
- Article
The symbolic two-step method applied to cancer care delivery research: Safeguarding against designing an underpowered cluster randomized trial with a continuous outcome by accounting for the imprecision in the within- and between-center variation.
- Published in:
- Clinical Trials, 2024, v. 21, n. 4, p. 430, doi. 10.1177/17407745231219680
- By:
- Publication type:
- Article
The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 350, doi. 10.1177/17407745241240401
- By:
- Publication type:
- Article
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 267, doi. 10.1177/17407745241234652
- By:
- Publication type:
- Article
Applications of the partial-order continual reassessment method in the early development of treatment combinations.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 331, doi. 10.1177/17407745241234634
- By:
- Publication type:
- Article
The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing—Challenging the "more is better" dogma.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 358, doi. 10.1177/17407745241232428
- By:
- Publication type:
- Article
Dose optimization for cancer treatments with considerations for late-onset toxicities.
- Published in:
- Clinical Trials, 2024, v. 21, n. 3, p. 322, doi. 10.1177/17407745231221152
- By:
- Publication type:
- Article